A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin’s Lymphoma (NHL)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512390-27-00

Acronym

BYON4228.001

Enrollment

Registered

2024-07-03

Start date

2023-06-09

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/refractory CD20 positive B-cell Non-Hodgkin's Lymphoma (NHL)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Italy, Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026